Camelina sativa is an oil seeded plant. The major component in the Camelina oil composition is the omega-3 fatty acid .The aim of this study was evaluation of the safety and efficacy of Camelina oil extract capsules in patients suffering from dry eye symptoms.

A randomized, triple-blind, interventional, placebo-controlled study was done. Fifty three patients were randomized in two groups to receive either two capsules containing 500mg of Camelina oil extract or placebo daily for 3 months. Uncorrected distance visual acuity (UCVA), tear film break-up time (TBUT), Schirmer’s test, tear meniscus height (TMH) and Ocular Surface Disease Index (OSDI) score were recorded at baseline and 3 months after intervention.

After three months, in Camelina group, the mean TBUT and TMH was significantly improved (P-Value < 0.05). Also the OSDI score was significantly reduced from 30.25 to 25.58. (P-Value < 0.05). In Placebo group, the OSDI was significantly reduced from 34.65 to 20. Comparison between these groups showed that UCVA (p=0.040), TBUT (p=0.027) and TMH(p=0.034) were significantly increased in Camelina than placebo group. There was not any serious complication in patients enrolled in this study.

Consumption of 1000 mg of Camelina oil extract is safe in patient with dry eye. This supplement can reduce the dry eye syndrome. For more validation, a multicentral clinical study with large sample size is proposed.